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ABSTRACT 
TITLE: PREDICTION OF RETINOPATHY USING THE WINROP SCREENING 
ALGORITHM IN A SOUTH AFRICAN POPULATION 
 
Introduction 
WINROP (Weight, IGF-1, Neonatal Retinopathy of Prematurity) is an online 
screening algorithm with sensitivities of 84.7 – 100% for severe ROP in other 
countries. The aim of this study is to test the efficacy of WINROP as a screening 
tool in a South African population. 
 
Methods 
This retrospective record review included infants born between 1 January 2013 
and 1 December 2014 who underwent ROP screening. Gestational age, date of 
birth, weekly weights and final ophthalmology screening results were entered into 
WINROP. The outcomes of ophthalmology clinical examinations were compared 
to alarms triggered on the system. Sensitivity and specificity, positive predictive 
and negative predictive values, the mean time of alarm and average weight gain 
per week were calculated. Results were compared between patients with 
complete and missing weekly weights. 
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Results 
Two hundred and twenty infants were included with a mean gestational age of 
29.1 weeks (SD 1.8 weeks), and a mean birth weight of 1115.5g (SD 201.0 
grams). Infants with complete weights totalled 193 patients with a mean 
gestational age of 29.1 weeks (SD 1.8 weeks) and a mean birth weight of 1115.8g 
(SD 201.2 grams), with no statistical difference between groups. The rates for all 
stages/severity of ROP were 5.9% and 2.3% for severe ROP. Weekly weight gain 
ranged between 4.6 to 83.8g/kg per week. WINROP triggered a high risk alarm in 
70.5% of infants at a mean of 30.7 weeks gestational age. The sensitivity for 
severe ROP was 100%, but 76.9% for ROP in all infants and 83.3% in the 
complete weight group. The specificity was low for both severe and all ROP at 
30.2% (complete weights 26.6%) and 30.0% (complete weights 26.5%) 
respectively. 
 
Conclusion 
Our rates of ROP are low. Rates of severe ROP have been found to be lower in 
African populations. The high number of alarms with a low negative predictive 
value, would reduce the number of screens by 29.5%. The alarms were triggered 
before scheduled screening, possibly helpful in planning discharges and follow up 
visits. The poor growth rates postnatally may have resulted in the increased 
alarms. This may be due to lower levels of IGF-1 and absolute weight gain 
postnatally in black infants. Screening algorithms relying on growth and IGF-1 
levels are race dependent, which needs to be considered in future algorithms for 
African populations. 
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PREFACE 
Retinopathy of prematurity (ROP) is an important cause of childhood blindness. 
There are many obstacles to screening for this complication in a developing 
country including large numbers of premature infants, stretched neonatal care 
resources and inadequate numbers of trained ophthalmology specialists. In 
addition, many infants are discharged prior to their screening examinations, and 
often lost to follow up. After reading about the WINROP (Weight, IGF-1, Neonatal 
Retinopathy of Prematurity) algorithm, I questioned if this screening tool would be 
useful in planning ROP screening by prioritising those infants at high risk of ROP 
in our setting at Chris Hani Baragwanath Academic Hospital. No studies have 
been done on an African population, and so I felt it would be important to 
investigate WINROP’s efficacy in predicting ROP at Chris Hani Baragwanath 
Academic Hospital. 
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CHAPTER 1  
1. INTRODUCTION 
1.1 Background 
 
Retinopathy of prematurity (ROP) has been found to be the third leading cause of 
avoidable blindness worldwide and forms part of the World Health Organisation 
(WHO) Vision 2020 Targets[1]. In South Africa, it has been shown to be 
responsible for 10.6% of cases of childhood blindness[2]. 
 
Terry initially described the most severe form of retinopathy of prematurity as 
retrolental fibroplasia in the 1940’s[3]. This first epidemic of ROP followed the 
injudicious use of supplemental oxygen in the 1940’s and 1950’s[4]. The second 
epidemic developed in the 1960’s with the increased survival of extreme low birth 
weight infants in developed countries[5]. Currently a third epidemic is taking place 
in developing countries. It is in these settings where the neonatal intensive care is 
still evolving, oxygen therapy is often liberally used and inadequately monitored[5].  
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1.2 Epidemiology 
 
Globally the incidence of ROP varies greatly, correlating with Infant Mortality 
Rates (IMR’s) and the socioeconomic state of countries. Low and lower middle 
income countries (LMIC), often with a high IMR greater than 60 per 1000 live 
births, do not have sufficient neonatal intensive care facilities and so preterm 
infants often do not survive to develop ROP. Countries with IMR’s of less than 9 
per 1000 live births are usually high income countries that can offer premature 
infants neonatal intensive care and thus good chances of survival and appropriate 
treatment of ROP. The intermediate group with IMR’s of 9 – 60 per 1000 live births 
is a high risk group for ROP as many of these middle income countries have 
improved survival of premature infants but suboptimal oxygen therapy, ROP 
screening and treatment[5]. 
 
A systematic review grouped studies done between 2000 and 2010 into 
categories based on their neonatal mortality rates (NMR). This was done in order 
to estimate the quality of newborn care and the proportion of neonatal units with 
an ROP programme.  Data was inadequate with regards to the coverage of 
screening for ROP in all settings and estimates were made based on expert 
opinion. Screening was assumed to be close to universal in countries with NMR 
below 5, 40% in countries with a NMR between 5 and 15, and 20% in countries 
with a NMR greater than 15. It was found that in countries with a NMR less than 5 
per 1000 live births, 21.89% of survivors developed any stage of ROP. In 
 3 
countries with a NMR greater or equal to 5 per 1000 live births, 36.5% of neonates 
would develop ROP of any severity[6]. 
 
The United States of America, United Kingdom and Canada all reported severe 
ROP as defined by the ETROP study, in infants with mean gestational ages of 
less than 26 weeks, and mean birth weights of less than 800g. Severe ROP is 
found in larger, more mature infants in moderately and poorly developed countries 
in comparison. Argentina, Lithuania, Chile, Cuba, Brazil, Columbia, Peru, Ecuador, 
Vietnam and India showed mean gestational ages of 26.3 – 33.5 weeks and mean 
birth weights of 903g – 1527g to be associated with severe ROP[7]. 
 
There is little data regarding ROP in Africa outside South Africa. Data from 
schools for the blind in Uganda, Kenya, Eritrea, Malawi and Ethiopia showed that 
none of the pupils were blind secondary to ROP, and in Nigeria it was reported as 
the cause in only 0.5%[7]. 
 
In South African studies done at Groote Schuur Hospital and Tygerberg Hospital 
in the Western Cape, ROP of any severity was found in 19.2%[8] and 33.4%[9]  of 
infants respectively. In Gauteng, Kalafong Hospital showed any ROP in 24.5%[10] 
and Chris Hani Baragwanath Academic Hospital 16.3% of infants screened[11]. 
 
At Chris Hani Baragwanath Academic Hospital, Mayet et al found the mean birth 
weight of neonates with ROP to be 1093.7g, compared to those without ROP at 
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1215.6g. No severe ROP was found in infants above 1250g. Although ROP was 
found in 16.3% of infants threshold disease was only found in 1.6%.  A significant 
number were lost to follow up thus limiting the study. The study showed that 
gestational age was an unreliable factor to assess risk in our population due to 
infrequent first trimester ultrasound scans and often uncertain last menstrual 
periods[11]. 
 
The rates of severe ROP have been found to be lower in infants of African 
descent populations in studies in the United States of America and United 
Kingdom by Saunders for the Cryotherapy for Retinopathy of Prematurity 
Cooperative Group[12], Ying for the e-ROP Cooperative Group[13] and Husain in 
London[14]. In Israel, Monos also found that African infants were less likely to 
develop ROP, but also that this may be related to the amount of melanin in the 
choroid and retina. Infants with darker pigmented retinas have been found to have 
lower incidences of ROP. Dark skinned individuals have increased concentrations 
of melanin, which is a known free radical scavenger. As a significant part of the 
pathogenesis of ROP consists of oxygen toxicity and the generation of superoxide 
free radicals, the increased melanin may have a protective effect[15]. 
 
Another study in the United Kingdom found that the infants of African descent, 
along with Asian infants had a higher rate of ROP when compared to white infants 
even after adjustments were made for birth weight and gestational ages. It has 
been suggested that this difference may be due to more African infants being 
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small for gestational age, as well as having better survival rates than their white 
counterparts[16]. 
 
1.3 Pathophysiology of Retinopathy of Prematurity 
 
Vasculogenesis of the retina usually starts at approximately 12 weeks gestation in 
utero when the vascular precursor cells lay down the framework. The increased 
metabolic demands of the maturing retinal neurons spur on angiogenesis at 
approximately 17 weeks gestation, building onto the vascular framework and 
radiating outward from the optic nerve. The relative physiological hypoxia from this 
metabolic demand results in the release of Vascular Endothelial Growth Factor 
(VEGF) stimulating new vessel formation. In the retina Insulin-like Growth Factor – 
1 (IGF-1) regulates VEGF, and a minimum level is required for maximum 
signalling of the pathways involved [17, 18]. 
 
The pathophysiology of ROP is understood to be due to abnormal vascularisation 
of the retina which takes place in two phases postnatally. Firstly at birth the 
relative hyperoxia of the ex-utero environment, with or without supplemental 
oxygen, leads to down regulation of hypoxia-driven growth factors and results in 
vascular obliteration[17]. In addition the lack of optimal levels of IGF-1 and essential 
fatty acids found in utero seem to contribute to the first phase of ROP[4]. 
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Secondly at 30 – 32 weeks pathological neovascularisation develops. As 
metabolic demands from the retina increase causing hypoxia, there is an upsurge 
in the release of growth factors in response resulting in neovascularisation. These 
new vessels remain on the border between the vascular and avascular retina and 
do not perfuse the avascular portion of the retina[17]. The abnormal vessels are 
also more permeable and result in fibrosis, scarring and at the most severe retinal 
detachment. The degree of ROP is dependent on the balance between the 
oxygen demand of the retina and the supply. In most cases ROP regresses 
spontaneously as the vascularisation of the retina progresses[4]. 
 
Thus, abnormal levels of postnatal growth factors such as VEGF and IGF-1, that 
impact on both vascular growth and weight gain would have an impact on the 
second stage of ROP.  The degree of avascularisation from the first stage of ROP 
has an influence on the extent of the second stage of ROP.   
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1.4 Risk Factors 
 
Risk factors can be classified into prenatal and postnatal as represented in Table 
1.1.  
Table 1.1 Risk factors for Retinopathy of Prematurity [4,17,18,19,20] 
Prenatal  Postnatal 
 Birth weight 
 Gestational age 
 
 Hyperoxia 
 Poor postnatal nutrition 
 Low IGF-1 levels and poor 
postnatal growth 
 Neonatal infection 
 Hyperglycaemia, insulin use 
 
 
Prenatal factors determine how vulnerable the retina is to the stresses that could 
result in abnormal vascular development. The more premature the infant is, the 
more immature the neural and vascular tissues, and so the higher the risk of 
damage. In addition, a very premature infant will be hospitalised for a longer 
period, which exposes them to more postnatal risks [4, 17]. It has also been found 
that poor intra-uterine growth resulting in being born small for gestational age is an 
additional risk for ROP[18]. 
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As the prenatal factors are determined at birth, the postnatal risks are modifiable 
targets for prevention and therapy. The first risk factor is the relative hyperoxia at 
birth and the secondary suppression of the growth factors. The balance between 
prevention of ROP and mortality guide oxygen saturation targets and the strict 
management of oxygen therapy is a known important strategy in avoidance of 
ROP[4, 17, 19]. 
 
Secondly factors lacking in the postnatal environment usually found in-utero that 
support normal retinal development during the third trimester are more recent 
subjects of research.  Premature infants have increased metabolic requirements 
than they would have had in utero having to generate heat, adapt to the postnatal 
environment and overcome complications such as chronic lung disease. Enteral 
feeding is also complicated with an immature gastrointestinal tract, and 
intravenous nutrition only provides the basic nutritional requirements[18]. Premature 
infants do not receive the large amount of omega 3 and omega 6 fatty acids 
transferred transplacentally during the third trimester. The balance between these 
two essential fatty acids is vital in the survival in both the vascular and neural cells 
in the retina[17]. Hyperglycaemia and treatment with insulin have been shown to 
increase the risk of both mild and severe ROP[20] emphasising the importance of a 
balanced approach to nutrition.  
 
Low IGF-1 levels are also associated with poor postnatal weight gain and brain 
growth as measured by head circumference. In utero IGF-1 levels increase mostly 
during the third trimester[4]. After a preterm delivery the loss of the maternal-foetal 
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interaction results in a rapid decrease in these levels and a very slow increase due 
to reduced liver production secondary to immaturity and inadequate nutritional 
substrates[18]. 
 
Neonatal infections, in particular fungal infections also increase the risk of the 
development of ROP. This may be due to systemic inflammation associated with 
sepsis, which may worsen the effects of the hyperoxia[4]. 
 
By definition, ROP occurs only in preterm infants, as it requires an incompletely 
vascularised retina. In certain circumstances, however more mature infants can be 
at risk as well. Prenatal risks include pregnancy related hypertension. Postnatal 
asphyxia and hypoxia-ischaemic encephalopathy along with the infections 
mentioned previously can put term infants at risk of retinopathy.[21]. 
 
 
1.5 Classification of Retinopathy of Prematurity 
 
The International Classification of Retinopathy of Prematurity was initially 
developed in 1985 to provide a standardised description of the staging and 
location of disease. It has been updated in 1987 and 2005[22]. 
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The location is described in zones, which are concentric circles centred on the 
optic nerve, and includes the hours of a clock face to indicate the areas involved. 
The staging of the disease is determined by the most severe manifestation of the 
disease in the eye.  These are described in more detail in Table 1.2 and Figure 
1.1. Stage 1 and Stage 2 ROP are likely to spontaneously resolve, but Stage 3 is 
at risk of progressing and causing vision loss.  
 
Table 1.2. Staging of ROP 
The International Classification of Retinopathy of Prematurity[22] 
 Definition Description 
Stage 1 Demarcation Line Thin flat white line between 
vascular and avascular retina 
 
Stage 2 Ridge White or pink line with height 
extending above the plane of the 
retina 
 
Stage 3 Extraretinal Fibrovascular 
Proliferation 
Neovascularisation extending into 
the vitreous makes ridge appear 
ragged 
 
Stage 4 Partial Retinal Detachment Extrafoveal (4A) or Foveal (4B) 
 
Stage 5 Complete Retinal Detachment Funnel-shaped usually 
 
Plus Disease Arterial tortuosity of posterior retinal vessels and venous dilatation 
 
Aggressive 
Posterior  
(AP-ROP or 
Rush 
disease) 
Severe form of ROP with rapid progression.  
Posterior prominence of plus disease that does not always follow 
the usual stepwise progression in severity 
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Figure 1.1 Zones of Retinopathy of Prematurity[4]  
Right eye 
 
 
 
Figure 1.2 Stages of Retinopathy of Prematurity[23]  
(a) Stage 1 ROP; (b) Stage 2 ROP; (c) Stage 3 ROP; (d) Stage 4 ROP 
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Following on the The Early Treatment for Retinopathy of Prematurity (ETROP) 
study severe ROP was classified into Type 1 and Type 2 as described in Table 
1.3. Type 1 ROP requires treatment, whereas Type 2 requires serial follow up 
examinations with treatment if it progresses to Type 1[24].  
 
Table 1.3 The Early Treatment for Retinopathy of Prematurity (ETROP) 
Study[24]  
Type 1 ROP Type 2 ROP 
 Zone I, any stage ROP with plus 
disease 
 Zone I, stage 3, with or without plus 
disease  
 Zone II, stage 2 or 3 ROP, with plus 
disease 
 Zone I, stage 1 or 2 with no plus 
disease 
 Zone II, stage 3 with no plus disease 
 
 
1.6 Retinopathy of Prematurity Screening 
 
ROP screening programmes have a high sensitivity but low specificity. The aim is 
to prevent blindness in any child, but as a result only a very small proportion of 
those screened have positive findings, and an even smaller minority require 
treatment.  
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The WHO VISION 2020 targets for the control of blindness in children include 
ensuring that all infants at risk of ROP have a fundus examination by a trained 
observer 6–7 weeks after birth. Cryo or laser treatment should be provided for all 
those with threshold disease[1]. Worldwide screening guidelines vary. There are 
two main approaches to developing guidelines for screening: firstly, using 
gestational age and birth weight alone, and secondly using gestational age and 
birth weight along with illness criteria[25]. This second method takes the clinical 
course of the infant and the impact of known risk factors such as prolonged 
oxygen exposure into account.  
 
The timing of screening examinations is also not consistent. Some guidelines 
calculate the examinations to be done at postnatal ages regardless of gestational 
age at birth, for example WHO Vision 2020 suggests screening at 6 – 7 weeks 
postnatal age[1]. However most guidelines plan the examinations based on 
corrected gestational age (CGA). A schedule was developed from a meta-analysis 
which suggested first screening at a CGA of 31 weeks or postnatal age of 4 
weeks, whichever came latest. This also correlates with the natural history of 
ROP[26]. Screening is continued until the risk of ROP developing is minimal, 
usually at a CGA of 37 weeks or when zone 3 is vascularised clinically. If ROP is 
present on initial screening, the premature infant examinations continue at 1 – 2 
weekly intervals until regression is seen on at least two occasions[25]. 
 
In the United Kingdom the guidelines recommend all infants born at ≤1500 g 
and/or less than 32 weeks gestation should have an ophthalmology screen[27]. In 
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the USA Infants with a birth weight of ≤1500 g or gestational age of 30 weeks or 
less, and selected infants with a birth weight between 1500 - 2000 g or gestational 
age of >30 weeks with an unstable clinical course are recommended to be 
screened[28]. Both follow the schedule of examinations based on CGA of the 
patient.  
These screening programmes developed in first world settings are not always 
appropriate for middle and low-income countries. Thirteen percent of infants in 
middle and low income countries that were found to have ROP had birth weights 
and gestational ages greater than that of the United Kingdom screening criteria[7].      
 
To compound the problem, a shortage of specialised ophthalmology services and 
screening programmes in South Africa resulted in only 19.2% of infants that fulfil 
the screening criteria being examined by an ophthalmologist[29]. In the future 
telemedicine might improve coverage with the use of digital retinal imaging done 
by trained technicians rather than ophthalmologists and referral to centralised 
ophthalmology centres as required[30].  
 
 The South African guidelines suggests screening for all neonates born below 32 
weeks gestation, weighing < 1500g at birth or with risk factors such as family 
history, cardiac arrest, multiple blood transfusions, exchange transfusions and 
hypoxic ischaemic encephalopathy (HIE). It is recommended that examinations 
are done between 31 and 32 weeks corrected gestational age or between 4 and 6 
weeks chronological age, whichever is later[31]. The rates of ROP requiring 
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treatment from available screening programmes were low at 0.6 – 2.9% with all 
infants weighing <1200g at birth[29].  
 
At Chris Hani Baragwanath Academic Hospital previous studies have shown that 
gestational age is an unreliable factor to assess risk in our population due to 
infrequent first trimester ultrasound scans and often uncertain last menstrual 
periods. For this reason the screening criteria at Chris Hani Baragwanath 
Academic Hospital is based on birth weight[11]. 
 
The screening guidelines for retinopathy of prematurity as per Chris Hani 
Baragwanath Academic Hospital ROP guidelines are as follows: 
1. All infants with a birth weight of below 1500g  
2. Infants with a birth weight of 1500 – 2000g who received mechanical 
ventilation for more than 7 days 
3. Infants with a birth weight of 1500 – 2000g who received supplemental 
oxygen for more than 2 weeks 
4. Infants with any birth weight who received supplemental oxygen for 
more than 6 weeks will be included.  
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1.7 Treatment of Retinopathy of Prematurity 
 
The Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP) determined 
that a 50% reduction in retinal detachment was achieved with treatment at a 
specific time during the course of disease, referred to as threshold disease. It is 
defined clinically as at least five contiguous or eight cumulative clock hours of 
stage 3 ROP in zone I or II in the presence of plus disease [32].  
 
However visual acuity was still poor, with less than 20% of infants having a visual 
acuity better than 20/40. Subsequently The Early Treatment for Retinopathy of 
Prematurity Study (ETROP) found that earlier treatment results in improved visual 
outcomes. This is referred to as prethreshold disease. Following on the study it is 
recommended that peripheral retinal ablation should be considered for any eye 
with Type 1 ROP, defined as: 
 Zone I, any stage ROP with plus disease or  
 Zone I, stage 3, with or without plus disease or 
 Zone II, stage 2 or 3 ROP, with plus disease. 
 
Continued serial examinations as opposed to peripheral retinal ablation, should be 
considered for any eye with Type II ROP, defined as: 
 Zone I, stage 1 or 2 with no plus disease or  
 Zone II, stage 3 with no plus disease[24] . 
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Cryotherapy was initially the treatment of choice to ablate the non-vascularised 
retina, but laser ablation has subsequently replaced it as the gold standard of 
management[33]. Both these therapies prevent progression of ROP by destroying 
retinal cells producing VEGF. Inhibitors of VEGF such as bevacizumab have 
begun to gain favour as they have been shown to require repeat treatments less 
frequently[34], and have fewer ocular complications when compared to laser 
ablation. Intravitreal VEGF inhibitors such as bevacizumab injections do not 
permanently damage the retina as laser does, and allows the retina to continue to 
develop. This results in better visual fields and refraction. Concern does exist 
however regarding the systemic effects of these treatments on the developing 
organs in preterm infants, and further trials are needed to study their safety[35]. 
 
1.8 WINROP (Weight, IGF-1, Neonatal Retinopathy of Prematurity) 
 
WINROP is an algorithm developed by The Sahlgrenska Center for Paediatric 
Ophthalmology Research in Gothenburg, Sweden.  A model was sought that took 
known postnatal risks into consideration when predicting ROP along with prenatal 
factors of birth weight and gestational age. WINROP works from a reference 
model calculated using logistic regression with expected values from the weights 
and IGF-1 levels of infants with no or mild ROP. Alarms for the possible 
development of ROP were developed for deviations from the expected weight gain 
over time. Initially the algorithm required both weekly blood IGF-1 levels as well as 
weekly weights. Now the only data required is sex, gestational age at birth and the 
weekly weights to calculate the risk[36]. 
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WINROP showed 100% sensitivity for stage 3 ROP in the Swedish population[37]. 
This algorithm was then incorporated into a web-based computer program to 
calculate the alarms. A further prospective study of the online surveillance system 
again showed a sensitivity of 100%, specificity of 32% and positive predictive 
value of 24% for stage 3 ROP. For sight-threatening ROP the sensitivity was again 
100% with a specificity of 54% and a positive predictive value of 41%, thus 
indicating its usefulness as a screening tool[38]. 
 
The algorithm is accessed online after registration with the WINROP website 
(https://winrop.com) with a password protected login. Patients can either be 
entered anonymously or as named patients. Once the weekly weights have been 
entered risk is indicated as red or green lamps indicating high or low risk 
respectively. The timing of a high risk alarm is also indicated in gestational age in 
weeks. The final ophthalmology examination is also inserted into the online 
database.  
 
A retrospective study in the USA using the WINROP online statistical surveillance 
program with only weekly weights still showed 100% sensitivity with all infants with 
severe ROP infants triggering an alarm. These infants triggered an alarm at a 
median of 3 weeks of age, 9 weeks before the diagnosis of severe ROP. In the 
infants that did not trigger an alarm or triggered a low risk alarm, none developed 
more than mild ROP and all regressed without treatment. As all the infants that 
developed severe ROP triggered a high risk alarm, and these patients totalled 
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25% of those screened, it was postulated that the number of screens could be 
reduced by 75%[36]. 
 
WINROP has been validated using retrospective cohort studies for the prediction 
of severe ROP in Switzerland (sensitivity 90%)[39], Brazil (sensitivity 90.5%)[40], 
North America (sensitivity 100% and 98.6% in two studies) [36, 41], Mexico 
(sensitivity 84.7%)[42], China (sensitivity 87.5%)[43], South Korea (sensitivity 
90%)[44], and Scotland (sensitivity 87.5%)[27]. The prediction tool is simple to use 
and is implemented in 47 countries by 256 caregivers. It has been useful in 
highlighting the patients at highest risk in order to prioritise and initiate early 
interventions, and thus managing resources appropriately[45]. No data has been 
published regarding the efficacy of WINROP in an African population, which is the 
objective of this study.  
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CHAPTER 2 
2. AIM, OBJECTIVES AND METHODS 
 
2.1 Aim 
 
This study aimed to assess the efficacy of WINROP as a screening tool in 
predicting ROP in infants undergoing ROP screening at Chris Hani Baragwanath 
Academic Hospital.  
 
2.2 Objectives 
 
We used the following objectives to evaluate WINROP as a screening tool in our 
population:  
 
2.2.1 Sensitivity 
In order to evaluate the proportion of true positives correctly identified by the 
WINROP screening algorithm, sensitivity was calculated. This reflects the rate of 
pick-up of ROP by WINROP. 
  
2.2.2 Specificity 
The specificity was calculated to assess how efficiently the WINROP screening 
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algorithm excluded the possibility of ROP by calculating the proportion of true 
negatives. 
 
2.2.3 Positive Predictive Value 
The proportion of those with a high risk alarm on the WINROP screening algorithm 
who have ROP was calculated and reflected in the positive predictive value.  
 
2.2.4 Negative Predictive Value 
The negative predictive value was used to assess the proportion of those without 
high risk alarms on the WINROP screening algorithm who did not have ROP. 
 
2.2.5 Positive likelihood Ratio 
The positive likelihood ration was used to determine the effect of a high risk alarm 
on the WINROP screening algorithm on the odds of having ROP.  
 
2.2.6 Mean time of Alarm 
When inserting data into the online algorithm those infants that deviate from the 
growth predicted trigger an alarm depicted as a red lamp on screen. This indicates 
that they are at high risk of ROP. Note was made of the corrected gestational age 
when the alarm was triggered. This was to determine if this occurred earlier than 
the scheduled ophthalmology screening examinations.   
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2.2.7 Comparison of Complete and Incomplete Weights 
Not all the infants were weighed consistently every week. In order to determine the 
effect of incomplete weights on the efficacy of the screening tool we compared 
infants with complete weights with those with missing weekly weights.  
 
2.2.8 Rates of ROP 
The rates of ROP were calculated using the number of infants diagnosed with 
ROP born over a two year time period. This is described in more detail below. The 
rates may not be a true incidence rate as this was a retrospective record review of 
inpatient files. Some notes may have been missing, and some infants may have 
missed ophthalmology screening or completed their screening as outpatients.  
 
 
2.3 Methods 
2.3.1 Study Design  
 
This study was a retrospective review of the records of patients who underwent 
ROP screening as per guidelines at Chris Hani Baragwanath Academic Hospital. 
Registration for WINROP was undertaken prior to commencement of the study 
with The Sahlgrenska Center for Pediatric Ophthalmology Research, allowing us 
access to the online programme with a password protected login.  
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Weekly ROP screenings are performed by registrars in ophthalmology, and 
referred to consultants as required. ROP was classified according to the 
International Classification of ROP[22]. The ophthalmology reports of the routine 
ROP screenings were reviewed along with the patient records to obtain the 
required data. As only the inpatient records were available for review, only screens 
done as an inpatient could be recorded. Not all patients had completed ROP 
screening by the time of discharge and so the type or severity of ROP diagnosis at 
time of discharge was used for the study.  This data was entered into a 
modification of the current ophthalmology request form for ROP (see Appendix A).  
 
The gestational age, date of birth, weekly weights and final ophthalmology 
screening results were entered into the online WINROP algorithm. Patient 
identifiers such as names and hospital numbers were recorded in a separate 
document to ensure confidentiality.  
 
The ETROP study[24] was the basis for the categorisation in the study. This was in 
order to maintain uniformity with other studies evaluating ROP. Patients were 
classified as follows:   
1. No ROP (immature or mature vascularization) 
2. Mild ROP (stage 1 or 2 ROP in zone II or III, without plus disease) 
3. Severe ROP (any prethreshold, any stage 3, or threshold ROP)[35]. 
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2.3.2 Study Population 
 
2.3.2.1. Inclusion criteria 
1. Premature infants born between 1 January 2013 and 31 December 2014 
who underwent at least one ophthalmology ROP screening examination 
2. Premature infants with a gestational age at birth equal to or less than 32 
weeks 
WINROP can only be used reliably for a gestational age at birth of 23 
weeks + 0 days to 31 weeks + 6 days. For this reason infants screened by 
the ophthalmology unit as per the guidelines at 32 weeks were included to 
fulfil the criteria of 31 weeks. Due to the majority of the gestational ages in 
our study being calculated by examination with the New Ballard Score[46], 
which estimates gestation to full weeks, those at 32 weeks were included 
as 31 weeks + 6 days.  
3. Premature infants with a birth weight below 1500g, as per Chris Hani 
Baragwanath Academic Hospital guidelines 
 
The screening guidelines for retinopathy of prematurity as per Chris Hani 
Baragwanath Academic Hospital ROP guidelines are as follows: 
 All infants with a birth weight of below 1500g  
 Infants with a birth weight of 1500 – 2000g who received mechanical 
ventilation for more than 7 days 
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 Infants with a birth weight of 1500 – 2000g who received supplemental 
oxygen for more than 2 weeks 
 Infants with any birth weight who received supplemental oxygen for 
more than 6 weeks will be included 
 
2.3.2.2 Exclusion criteria 
Neonates that were noted to have conditions leading to disproportionate weights 
such as hydrocephalus were excluded.  
 
 
2.3.3 Statistical analysis 
 
A required sample size of 207 was calculated using a frequency of 16.3% for any 
ROP, allowing a margin for error of 5% and a total of 220 patients were included.  
 
Once the data was compiled in the online programme, the database was exported 
as a spreadsheet. The outcomes of the ophthalmology clinical examinations were 
then compared to the alarms triggered on the system. Sensitivity and specificity, 
as well as positive predictive and negative predictive values were calculated 
based on high risk alarms and clinical findings of ROP. The mean time of alarm 
and average weight gain per week was also calculated. The average weight gain 
per week was calculated using the difference between subsequent average 
weights per gestational and chronological age. 
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Results were compared between those patients with complete weekly weights and 
those with missing weekly weights. Statistical software package Dell Statistica 
(Version 12) was used to analyse the characteristics of these two groups, using 
Chi-square tests for categorical variables and Student’s t-test for continuous data.  
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CHAPTER 3 
3. RESULTS 
 
3.1 Patient Characteristics 
 
A total of 220 infants were included in the study. The gestational age, birth weight, 
gender and ROP diagnosis are included in Table 3.1. The complete weight group 
consisting of 193 infants was also analysed as a group to evaluate the effect of 
missing weights on the efficacy of WINROP. The mean birthweight of all the 
infants was 1115g (standard deviation 201.0 grams). Birth weights were normally 
distributed. Gestational ages were slightly skewed towards the larger gestational 
ages although not significantly so with a median of 29 weeks (interquatile range 
28 – 30 weeks) and a mean of 29.1 weeks (standard deviation 1.8 weeks). This is 
likely because more mature infants have better survivial rates. For comparison 
with previous studies of WINROP the mean gestational age was used.  
 
There was no statistical difference in gestational age and weights between the 
infants with complete weights as compared to the infants with incomplete weights 
(p=0.32 and p=0.96). There were slightly more females (112, 50.9%) than males 
in the study population although not statistically significant. Almost 95% of the 
study population had no ROP when screened. There was no statistical difference 
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(p=0.60) in the rate of ROP between the complete weight and incomplete weight 
groups. (Table 3.1).   
 
Table 3.1 Patient Characteristics and Rates of ROP 
 All infants Complete 
weights 
Incomplete 
weights 
P 
value 
Number 220 
 
193 27  
Mean gestational age (weeks) 
(±SD)  
29.1 
(±1.8) 
29.1 
(±1.8) 
28.7 
(±2.0) 
0.32* 
Mean birth weight (grams) 
(±SD)  
1115.5 
(±201.0) 
1115.8 
(±201.2) 
1113.7 
(±203.5) 
0.96* 
Male gender  
n (%) 
108 (49.1%) 92 (47.7%) 16 (59.3%) 0.25# 
No ROP 
n (%) 
207 (94.1%) 181 (93.8%) 26 (96.3%) 0.60# 
ROP mild 
n (%) 
8 (3.6%) 7 (3.6%) 1 (3.7%)  
ROP severe 
n (%) 
5 (2.3%) 5 (2.6%) 0  
ROP treated as inpatient 
n (%) 
2 (0.9%) 2 (1.0%) 0  
* Students t-test, # Chi-square 
 
3.2 Rates of Retinopathy of Prematurity 
 
The rates of ROP in our population were low with any severity of ROP at 5.9% and 
severe ROP at 2.3% (Table 3.1). Most of the patients with ROP were in the 
complete weight group, with only one patient with mild ROP missing weights. Two 
patients were treated with bevacizumab injections by the ophthalmology unit as 
inpatients. 
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3.3 Average weight gain  
 
Using the database of weekly weights, an estimation of weekly weight gain had 
been created. The weekly weight gain ranged between 4.6 to 83.8g/kg per 
chronological week. This is represented in Table 3.2 and Figure 3.1 shows the 
average weight gain per week. The number of infants per chronological week is 
included to demonstrate the reduction in numbers as the chronological weeks 
progress, which may have resulted in the average weight gain being less 
significant as seen in week 9 in Table 3.2. 
 
 
Figure 3.1 Average Weight per Chronological Week 
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Table 3.2.  Average Weight per Chronological Week 
 
Chronological 
week 
Number of 
infants 
Average 
weight (g) 
Mean (±SD) 
Average gain 
per week (g) 
Average gain 
per week 
(g/kg) 
1 220 1115.5 
(±220.6) 
  
2 197 1057.6 
(±192.7) 
- 57.9 -51.9 
3 210 1117.4 
(±196.8) 
59.8 56.5 
4 211 1211.1 
(±217.2) 
93.9 84.0 
5 214 1309.4 
(±231.1) 
98.3 81.2 
6 154 1366.8 
(±232.1) 
57.4 43.8 
7 114 1413.6 
(±244.0) 
58.2 42.6 
8 71 1490.7 
(±286.9) 
65.7 46.5 
9 20 1497.5 
(±184.0) 
6.8 4.6 
10 9 1560.6 
(±236.7) 
63.1 40.4 
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The weekly weight change ranged from a loss of 79.6g to a gain of 83.7g when 
calculated on weights according to corrected gestational age. This is represented 
in Figure 3.2 and Table 3.3. The number of infants per gestational age in weeks is 
included to demonstrate the reduced numbers in the earliest corrected gestational 
ages, which may have impacted on significance of the calculations at these 
corrected gestational ages.  
 
Figure 3.2 Average Weight per Corrected Gestational Age 
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Table 3.3.  Average Weight Gain per Corrected Gestational Age 
 
Corrected 
gestational 
age (weeks) 
Number of 
infants 
Average 
weight (g) 
(±SD) 
Average gain 
per week (g) 
Average gain 
per week 
(g/kg) 
24 1 955   
25 3 875.3 
(±68.3) 
-79.7 -83.5 
26 21 954.4 
(±145.7) 
79.0 90.3 
27 37 950.8 
(±145.1) 
-3.6 -3.8 
28 94 1016.9 
(±164.7) 
66.1 71.3 
29 113 1030.2 
(±173.9) 
13.3 13.1 
30 162 1103.4 
(±182.2) 
73.2 71.1 
31 210 1176.7 
(±202.9) 
73.3 66.4 
32 209 1238.0 
(±208.7) 
61.3 52.1 
33 212 1321.7 
(±232.4) 
83.7 67.6 
34 197 1403.5 
(±243.2) 
81.8 61.9 
35 165 1472.1 
(±255.3) 
68.6 48.9 
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3.4 Efficacy of WINROP  
 
3.4.1 Alarm 
 
The WINROP programme triggered a high risk alarm in 155 out of 220 infants 
(70.5%) at a mean of 30.7 weeks gestational age. Seventeen infants triggered an 
alarm at birth for being significantly small for gestational age; although none went 
on to develop any ROP. 
 
3.4.2 Sensitivity, Specificity, Positive Predictive Value and Negative 
Predictive Values  
 
The sensitivity, specificity, positive predictive values (PPV), negative predictive 
values (NPV) and positive likelihood ratios were calculated for all infants as well as 
for those with complete weights, and for all stages of ROP and severe ROP (Table 
2.3). All the severe ROP patients triggered a high risk alarm. Compared to the 
sensitivity for severe ROP (100%), the sensitivity for all stages ROP was reduced 
at 76.9% in all infants and 83.3% in the complete weight group. The specificity 
was low in all groups, with such a large number of the total infants triggering 
alarms, due to poor weight gain. The positive likelihood ratios were 1.1 for all 
stages of ROP, and 1.4 for severe ROP.  
 
 34 
All patients with any stage of ROP were due for follow up with the ophthalmology 
department as outpatients at one to three weeks after the last screen. These 
records were unavailable for the purposes of this study, so it is unknown if the 
ROP regressed or worsened.  
 
Table 3.4. Results for all patients with any stage of ROP 
 Disease No Disease  
Test positive  10 145 155 
Test negative 3 62 65 
 13 207 220 
 
Sensitivity = 10/ (10+13) = 76.9% 
Specificity = 62/(62+155) = 30.0% 
PPV = 10/(10+145) = 6.5% 
NPV = 62/(62+3) = 95.4% 
 
 
 
Table 3.5. Results for patients with complete weights with any ROP 
 Disease No Disease  
Test positive  10 133 143 
Test negative 2 48 50 
 12 181 193 
 
Sensitivity = 10/(10+2) = 83.3% 
Specificity = 48/(48+133) = 26.5% 
PPV = 10/(10+133) = 7.0% 
NPV = 48/(48+2) = 96% 
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Table 3.6. Results for all patients with severe ROP 
 Disease No Disease  
Test positive  5 150 155 
Test negative 0 65 65 
 5 215 220 
 
Sensitivity = 5/(5+0) = 100% 
Specificity = 65/(65+150) = 30.2% 
PPV = 5/(5+150) = 3.2% 
NPV = 65/(65+0) = 100% 
 
 
Table 3.7. Results for patients with complete weights with severe ROP 
 Disease No Disease  
Test positive  5 138 143 
Test negative 0 50 50 
 5 188 193 
 
Sensitivity = 5/(5+0) = 100% 
Specificity = 50/(50+138) = 26.6% 
PPV = 5/(5+138) = 3.5% 
NPV = 50/(50+0) = 100% 
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Table 3.8 WINROP performance in predicting ROP 
 Severe ROP All ROP 
 All infants Complete 
weights 
All infants Complete 
weights 
Sensitivity 100% 100% 76.9% 83.3% 
Specificity 30.2% 26.6% 30.0% 26.5% 
NPV 3.2% 3.5% 6.5% 7.0% 
PPV 100% 100% 95.4% 96% 
Positive 
likelihood ratio 
1.4 1.4 1.1 1.1 
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CHAPTER 4 
4. DISCUSSION 
 
The rates of ROP in our population were found to be low at 5.9% for any severity 
of ROP and 2.3% for severe ROP, when compared to other populations in the 
upper middle income countries[47].  
 
The patient population at Chris Hani Baragwanath Academic Hospital is largely 
African with the vast majority of patients being of black race. A study by Mayet et 
al from 2001 – 2003 found that 99% of infants screened for ROP at Chris Hani 
Baragwanath Academic Hospital were of black race, and only those of black race 
were used for analysis. Rates of ROP were low compared to other upper middle 
income countries with ROP of any severity at 16.3% and stage 3 ROP at 2.5%[11]. 
This is despite the neonatal unit having far fewer oxygen blenders and less 
stringent oxygen targets at the time.  
 
A study done at Kalafong Hospital in 1999 by Delport et al also only analysed the 
black infants screened. The rates of ROP were higher in comparison in this 
population with any stage of at ROP 24.5% and stage 3 ROP at 6.4%[10]. This is 
still lower than the rates in most upper middle income populations. Unfortunately, 
other studies on ROP in South African populations have not commented on race 
for further comparison.   
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High risk alarms were triggered by a large proportion of infants at Chris Hani 
Baragwanath Academic Hospital (70%) despite the low rate of ROP (5.9%), 
resulting in a low negative predictive value. As a comparison in other countries 
who have studied WINROP, only Mexico had more alarms at 79.2%, but also 
found severe ROP in 56.3% of their infants. In this population, ROP was found in 
larger more mature infants. It was also disclosed that gestational age estimates, 
antenatal care, oxygen monitoring were suboptimal[42]. Elsewhere the rates of 
alarms were lower but still with higher rates of ROP than our population as 
demonstrated in Table 4.1.  
 
Table 4.1: Comparison of WINROP Alarms, Rates of Severe ROP, Gestational 
Age and Birth Weight from Studies Conducted Worldwide 
 WINROP 
Alarms 
ROP severe GA 
(weeks) 
BW 
(grams) 
CHBAH 70.5% 2.3% 29.1 1115.5 
Mexico[42] 79.2% 56.3% 31 1420* 
China[43] 18.5% 9.8% 30 1416 
Brazil[40] 47% 5.7% 30 1215 
Korea[44] 52.9% 12.7% 29.3 1263.7 
Scotland[27] 43.4% 12.3% 28.8 1201.8 
USA[36] 25.5% 8.8% 29 1050 
Sweden 
(ELBW)[48] 
78.4% 69% 25+4 784 
* Only gives the birth weight and gestational age of Stage 1 ROP. 
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The sensitivity of WINROP in our study was 100% for severe ROP with or without 
complete weights, but reduced for any stage of ROP at 76.9%. The subgroup with 
complete weights did however show an improved sensitivity of 83.3% for any 
stage of ROP.  However, when calculating the positive likelihood ratios the range 
of 1.1 – 1.4 only indicates a minimal increase in the likelihood of disease with a 
high risk alarm.  
  
The high number of alarms appears to be related to our poor growth rates 
postnatally, which deviate from the algorithm used by WINROP. The average 
weight gain of 0.66g to 12g per day is far below the 15 – 17g/kg per day 
recommended[49] . The small numbers of infants found on the extremes of both 
chronological and gestational age made the calculations of average weight gain 
per week distort from the middle age averages, although all the averages were still 
far below the recommended average weight gain per day. What seems to be 
unique in our study is despite the high rate of alarms our numbers of ROP remain 
low. 
 
At Chris Hani Baragwanath Academic Hospital it is often challenging obtaining 
expressed breast milk (EBM) in the first few days of life. The mothers of the 
preterm infants are often unwell, and have difficulties producing milk. For this 
reason we make use of a donor expressed breast milk (DBM) reserve for those 
with insufficient maternal EBM. This is unfortunately often inadequate for the large 
number of preterm infants that are treated in the neonatal unit. Although DBM is 
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donated, screening and processing the milk is costly. In a study in the United 
States of America the cost was quoted as $4 (approximately R48 at current 
exchange rates) per 30ml, excluding transport in 2011. It was calculated that in a 
population of infants <1500g and <33 weeks gestational age, the average cost for 
DBM ranged from $27 to $590 (approximately R327 – R7138 at current exchange 
rates) depending on the available maternal milk[50]. The Neonatal Unit at Chris 
Hani Baragwanath Academic Hospital gets 20 bottles of 200 mls each per week. 
This is not enough to cater for the ever-growing premature population. There is a 
unit policy of which infants are eligible for DBM and once screened to be eligible 
for DBM the infant only receives the DBM for two weeks. 
 
The large burden of HIV in our population also affects preterm infant feeding and 
growth. In 2015 Statistics South Africa estimated 18.99% of woman between the 
ages of 15 and 49 years were HIV positive[51]. Mixed feeding has been found to 
increase HIV transmission and decrease survival[52]. This forces us to depend on 
EBM from the mother or the limited breast milk reserve. As a referral hospital 
many patients are transferred from distant centres, and inadequate lodger facilities 
results in insuffient EBM from mothers who often do not have the finances to travel 
into our centre daily. This places further burden on the breast milk reserve. Further 
study into the factors affecting our poor postnatal growth rates would be helpful. 
 
A study conducted in a multiracial London neonatal unit showed that black infants 
had lower levels of IGF-1 at 32 and 33 weeks gestation when compared to white 
patients. The mean IGF-1 levels for black infants were 9.7 μmol/L, 8.8 μmol/L and 
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9.4 μmol/L at 31, 32 and 33 weeks CGA respectively. This was significantly lower 
when compared to non-black infants’ levels at 14.3 μmol/L, 17.2 μmol/L and 22.3 
μmol/L over the same age range. As expected, along with the lower IGF-1 levels 
they had lower absolute postnatal weight gain. Despite these known risk factors 
the black infants still needed less treatment for ROP than the white infants[53]. It is 
known that the adult black population has lower IGF-1 levels than white 
populations[54] and this seems to be confirmed in infants too[53]. This would 
suggest that screening algorithms relying on growth and IGF-1 levels are 
population and race dependent which may account for the differences in efficacy 
of WINROP outside of Sweden, including in our study. 
 
Although black infants may not show the same growth as the white infants, our 
study does highlight an important deficiency in care with our growth rates being 
inadequate. Meta-analysis showed that human milk feeding might play a 
protective role in the prevention of any ROP as well as severe ROP[55]. Thus the 
promotion of early expressed breast milk for preterm babies is an area for 
improvement.  
 
In our resource scarce setting patients do not have the transport funds for 
repeated outpatient appointments. WINROP may assist in predicting those who 
are at highest risk of ROP and so need to prioritise screening, although the low 
positive likelihood ratio only gives a minimal increase in the likelihood of disease. 
With such a high number of alarms WINROP would only potentially reduce the 
numbers for screening by 30%. The alarm was triggered at a mean of 30.7 weeks 
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gestational age, which is before the routine screening by ophthalmology. This 
could perhaps assist in the planning of discharges and follow up visits in infants 
discharged before the screen, as frequently happens in our hospital with a 
discharge weight of 1650g. A database tracking the infants receiving ROP 
screening, including their WINROP risk alarm would assist in not only the 
management of these infants, but also give more accurate statistics on ROP.  
 
There is potential for further study in more rurally based health facilities where 
patients would require travel for the ophthalmology screening, as an alternative to 
telemedicine as the equipment and trained personnel are not yet available in our 
setting. 
 
 
 
 
 
 
 
 
 
 
 
 43 
CHAPTER 5 
5. LIMITATIONS 
 
A required sample size of 207 was calculated using a frequency of 16.3% for any 
ROP, allowing a margin for error of 5% and a total of 220 patients were included. 
In our study, the rates of ROP were lower than the previous study at 5.9% for any 
ROP. This would influence the accuracy of the sample size calculation, and 
therefore the power of the results. 
 
As this study was a retrospective record review it included only the files that were 
located. Only inpatient ROP screening examinations were used in this study as no 
outpatient records were available. Many preterm infants were discharged prior to 
their first screening examination and were referred to the ophthalmology unit as 
outpatients. Some infants had initial screening examinations as inpatients, but 
were discharged prior to follow up examinations as outpatients. In these cases we 
could only include the screens documented in the inpatient file and not their final 
review by the ophthalmology unit. This may have influenced our results as I am 
not certain of the final diagnosis or stage of ROP in these infants, but rather using 
the diagnosis or stage at time of discharge.  
 
The examinations are done by the ophthalmology registrars and referred to 
consultants as required. There is rotation of the registrars and so perhaps no 
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consistency with regards to examiners doing the screening examinations which 
may create some bias.  
 
In the vast majority of our infants early antenatal ultrasounds were not performed. 
Gestational ages antenatally are often based on last normal menstrual peroid or 
symphasis-pubis measurements during pregnancy. Postnatally infants are 
expected to have a New Ballard Score performed to estimate their gestational 
age. This is usually undertaken by junior doctors working in the labour ward. The 
inexperience of these doctors may cause erroneous estimations of gestational 
age, which influences the performance of WINROP as an algorithm.  
 
Race was unfortunately not documented as part of the data collected. This would 
have been useful considering the findings related to rates of ROP and growth of 
African infants. There is no data available regarding the race of patients admitted 
to the unit during the time period, although the vast majority of our population is 
black.  As this was a retrospective study limited by incomplete records, data 
regarding the severity of illness and duration of oxygen therapy was not collected 
This may have provided interesting comparison to the severity of ROP.  
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CHAPTER 6 
6. CONCLUSION AND RECOMMENDATIONS 
 
Rates of ROP are low at Chris Hani Baragwanath Academic Hospital. This may be 
due to the vast majority of patients being African, which is known to be a 
protective factor against ROP due to the anitioxidant properties of melanin 
pigments.  
 
WINROP showed 100% sensitivity but a low specificity and low negative predictive 
value secondary to a large proportion of high risk alarms. The likelihood of disease 
was only minimally increased with a high risk alarm. It appears that the test would 
be of limited benefit in our population.  
 
The increased alarms were due to poor postnatal weight gain that differed from 
the expected weights calculated for the WINROP algorithm. The cause of poor 
growth in our infants is multifactorial and requires further investigation.  
 
Our study seems to confirm that IGF-1 levels and growth are population and race 
dependent, resulting in differences in the performance of WINROP compared to 
those in other parts of the world. This could form the basis of a future prospective 
study. 
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A future prospective study would be useful at a district or rural hospital where 
ophthalmology review is logistically difficult or not available as some benefit may 
be offered by reducing the number of referrals.  
 
A database containing the ROP screening examinations and WINROP alarms of 
infants could be a helpful tool, and perhaps be part of a prospective study in the 
future. Such a database may be useful in creating a complete ROP report for each 
infant, thus ensuring that fewer infants are lost to follow up. The high risk alarms 
would assist in prioritising patients for screening and early intervention. As our 
hospital is a tertiary referral centre it would be important to plan down referrals to 
centres without on site ophthalmology more carefully in high risk infants.  
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APPENDICES 
APPENDIX A: DATA SHEET 
ROP DATA SHEET     Study no:  
Gestational age:_________weeks      CGA at screening_______weeks          
 
Birth weight:_______________g     
Rh: Pos/Neg    RPR: Pos/Neg  HIV: Pos/Neg  
Ventilated: Yes/No  Date started: _______________; stopped: 
___________   
Oxygen: Yes/No  Date started: _______________; stopped: 
___________  
 NEC: Yes/No  TPN: Yes/No 
Culture positive sepsis: Yes/No  
 
Organism __________________ date of culture _________________________ 
Organism __________________ date of culture _________________________ 
Organism __________________ date of culture _________________________ 
Weights: 
Date CGA Weight 
   
   
   
   
   
   
   
 
Date of ROP Screen____/____/____       (day/month/year) 
1st Screen/2nd Screen 
Results: 
Zone1/Zone 2/Zone 3/Zone 4/Zone 5 
Preplus Disease /Plus Disease /Rush Disease   
Other: 
 
Discharge: Yes/No               Date of Rescreen: _____/_____/_____  
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